JMI LABS IS NOW PART OF LEARN MORE

Filter by Category: Antimicrobial Surveillance

Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010).

Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). by Sader HS, Moet GJ, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis 2011; 70 (3): 412-416

Eight-year (2002-2009) summary of the linezolid (Zyvox Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries

Eight-year (2002-2009) summary of the linezolid (Zyvox Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries by Ross JE, Farrell DJ, Mendes RE, Sader HS, Jones RN published in J. Chem. 2011; 23 (2):71-76

Results of the Canadian Ward Surveillance Study (CANWARD) (2007-2009), a journal symposium.

Results of the Canadian Ward Surveillance Study (CANWARD) (2007-2009), a journal symposium. by Jones RN published in Diagn. Microbiol. Infect. Dis. 2011; 69 (3): 288

Sustained antimicrobial activity of tigeycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States medical centers from 2004 through 2008.

Sustained antimicrobial activity of tigeycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States medical centers from 2004 through 2008. by Putnam SD, Sader HS, Farrell DJ and Jones RN published in J. Chemother. 2010; 22 (1): 13-16

Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 µg/mL isolated in the United States and European hospitals (2006-2008).

Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 µg/mL isolated in the United States and European hospitals (2006-2008). by Sader HS, Becker HK, Moet GJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 66 (3): 329-331

Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: Results from an international surveillance study.

Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: Results from an international surveillance study. by Jones RN, Mendes RE and Sader HS published in J. Antimicrob. Chemother. 2010; 65 (Suppl 4): iv17-iv31

Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009).

Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009). by Mendes RE, Farrell DJ, Sader HS, Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 68 (3): 307-311

Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).

Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008) by Mendes RE, Sader HS and Jones RN published in Int. J. Antimicrob. Agents. 2010; 36 (4): 374-379

Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.

Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. by Putnam SD, Sader HS, Moet GJ, Mendes RE and Jones RN published in Diagn. Microbiol. Infect. Dis. 2010; 67 (4): 359-368

Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. by Jones RN published in Clin. Infect. Dis. 2010; 51 (Suppl 1): S81-S87

Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres.

Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres. by Sader HS, Farrell DJ and Jones RN published in Int. J. Antimicrob. Agents 2010; 36 (1): 28-32

Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections.

Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. by Farrell DJ, Sader HS, Jones RN published in Antimicrob. Agents Chemother. 2010; 54 (6): 2735

Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.

Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. by Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I and Turnidge JD published in Diagn. Microb. Infect. Dis. 2009; 65 (4): 404-413

Linezolid surveillance program results for 2008 (LEADER Program for 2008).

Linezolid surveillance program results for 2008 (LEADER Program for 2008). by Farrell DJ, Mendes RE, Ross JE and Jones RN published in Diagn. Microb. Infect. Dis. 2009; 65 (4): 392-403

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008).

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). by Sader HS and Jones RN published in Diagn. Microb. Infect. Dis. 2009; 65 (2): 158-162

Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: Results from the DECIDE Surveillance Program (2007).

Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: Results from the DECIDE Surveillance Program (2007) by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect Dis. 2009; 64 (2): 177-184

ZAAPS International Surveillance Program (2007) for linezolid resistance: results for 5591 Gram-positive clinical isolates in 23 countries.

ZAAPS International Surveillance Program (2007) for linezolid resistance: results for 5591 Gram-positive clinical isolates in 23 countries. by Jones RN, Kohno S, Ono Y, Ross JE and Yanagihara K published in Diagn. Microbiol. Infect. Dis. 2009; 64 (2): 191-201

Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: Results from a global surveillance study (2003-2007).

Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: Results from a global surveillance study (2003-2007). by Fritsche TR, Sader HS, Stillwell MG, Jones RN published in Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 440-446

Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.

Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. by Mendes RE, Rhomberg PR, Bell JM, Turnidge JD, Sader HS published in Diagn. Microbiol. Infect. Dis. 2009; 63 (4): 415-425

Acinetobacter spp. infections: the Latin American scenario in the SENTRY Antimicrobial Surveillance Program (1997-2006)

Acinetobacter spp. infections: the Latin American scenario in the SENTRY Antimicrobial Surveillance Program (1997-2006), Lead author: Gales AC, presented at 18th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 19 – 22, 2008, Barcelona, Spain

Comparative activity of meropenem in US medical centers (2007): Initiating the 2nd decade of MYSTIC Program surveillance.

Comparative activity of meropenem in US medical centers (2007): Initiating the 2nd decade of MYSTIC Program surveillance. by Jones RN, Kirby JT and Rhomberg PR published in Diagn. Microbiol. Infect. Dis. 2008; 61 (2):203-213

IMP-producing Pseudomonas aeruginosa strain isolated in a US medical center: A recent arrival from Mexico.

IMP-producing Pseudomonas aeruginosa strain isolated in a US medical center: A recent arrival from Mexico. by Martin CA, Morita K, Ribes JA, Deshpande LM, Sader HS and Castanheira M published in Antimicrob. Agents Chemother. 2008; 52 (6): 2289-2290

Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986-2007).

Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986-2007). by Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS and Jones RN published in J. Clin. Microbiol. 2008; 46 (9): 2950-2954

Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates.

Increased antimicrobial susceptibility profiles among polymyxin-resistant Acinetobacter baumannii clinical isolates. by Mendes RE, Fritsche TR, Sader HS and Jones RN published in Clin. Infect. Dis. 2008; 46 (8): 1324-1326

United States resistance surveillance results for linezolid (LEADER Program for 2007).

United States resistance surveillance results for linezolid (LEADER Program for 2007). by Jones RN, Ross JE, Castanheira M and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2008; 62 (4): 416-426

Antimicrobial activity of doripenem tested against leading bacterial pathogens: Results from a Latin American surveillance study (2003-2006).

Antimicrobial activity of doripenem tested against leading bacterial pathogens: Results from a Latin American surveillance study (2003-2006). by Gales AC, Jones RN, Sader HS and Fritsche TR published in Braz. J. Infect. Dis. 2008; 12 (Suppl 2): 56-66

Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers.

Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. by Mendes RE, Sader HS, Deshpande L and Jones RN published in Diagn. Microbiol. Infect. Dis. 2008; 60 (4): 433-436

Metallo-beta-lactamase IMP-18 is located in a class 1 integron (In96) in a clinical isolate of Pseudomonas aeruginosa from Mexico.

Metallo-beta-lactamase IMP-18 is located in a class 1 integron (In96) in a clinical isolate of Pseudomonas aeruginosa from Mexico. by Garza-Ramos U, Tinoco P, Silva-Sanchez J, Morfin-Otero R, Rodriquez-Noriega E, Leon-Garnica G, Sader HS and Jones RN published in Int. J. Antimicrob. Agents 2008; 31 (1): 78-80.

Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States.

Antimicrobial activity of cefditoren tested against contemporary (2004-2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States. by Biedenbach DJ, Jones RN and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2008; 61 (2): 240-244

Activity of meropenem as serine carbapenamases evolve in US medical centers: Monitoring report from the MYSTIC Program (2006).

Activity of meropenem as serine carbapenamases evolve in US medical centers: Monitoring report from the MYSTIC Program (2006). by Rhomberg PR, Deshpande LM, Kirby JT and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 59 (4): 425-432

LEADER surveillance program results for 2006: An activity and spectrum of linezolid using clinical isolates from the United States (50 medical centers).

LEADER surveillance program results for 2006: An activity and spectrum of linezolid using clinical isolates from the United States (50 medical centers). by Jones RN, Fritsche TR, Sader HS and Ross JE published in Diagn. Microbiol. Infect. Dis. 2007; 59 (3): 309-317

Zyvox® Annual Appraisal of Potency and Spectrum Program results for 2006: An activity and spectrum analysis of linezolid using clinical isolates from 16 countries.

Zyvox® Annual Appraisal of Potency and Spectrum Program results for 2006: An activity and spectrum analysis of linezolid using clinical isolates from 16 countries. by Jones RN, Fritsche TR, Sader HS and Ross JE published in Diagn. Microbiol. Infect. Dis. 2007; 59 (2): 199-209

Daptomycin antimicrobial activity tested against methicillin-resistant staphylococi and vancomycin-resistant enterococci isolated in European medical centers (2005).

Daptomycin antimicrobial activity tested against methicillin-resistant staphylococi and vancomycin-resistant enterococci isolated in European medical centers (2005). by Sader HS, Watters AA, Fritsche TR and Jones RN published in BMC Infect. Dis. 2007; 7 (1) : 29

Impact of drug-exposure intensity and duration of therapy on the emergence Staphylococcus aureus resistance to a quinolone antimicrobial.

Impact of drug-exposure intensity and duration of therapy on the emergence Staphylococcus aureus resistance to a quinolone antimicrobial. by Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN and Drusano GL published in J. Infect. Dis. 2007; 195 (12): 1818-1827

Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype.

Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. by Sader HS, Hsiung A, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (3): 341-344

blaVIM-2 and blaVIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: Report from the MYSTIC Program.

blaVIM-2 and blaVIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: Report from the MYSTIC Program. by Aboufaycal H, Sader HS, Deshpande LM, Toleman M, Bodey G, Raad I and Jones RN published in J. Clin. Microbiol. 2007; 45: 614-615

Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC Program report from the Unite States component (2005).

Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC Program report from the Unite States component (2005). by Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (2): 207-215

Antimicrobial susceptibility of Gram-positive bacteria isolated from European Medical Centres: Results of the Daptomycin Surveillance Programme (2002-2004).

Antimicrobial susceptibility of Gram-positive bacteria isolated from European Medical Centres: Results of the Daptomycin Surveillance Programme (2002-2004). by Sader HS, Streit JM, Fritsche TR and Jones RN published in Clin. Microbiol. Infect. 2006; 12 (9): 844-852

Clonal occurrences of multidrug-resistant Gram-negative bacilli: Report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004).

Clonal occurrences of multidrug-resistant Gram-negative bacilli: Report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004). by Rhomberg PR, Fritsche TR, Sader HS, Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 54 (4): 249-257

Spectrum and potency of dalbavancin tested against 3,322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

Spectrum and potency of dalbavancin tested against 3,322 Gram-positive cocci isolated in the United States Surveillance Program (2004). by Jones RN, Stilwell MG, Sader HS, Fritsche TR and Goldstein BP published in Diagn. Microbiol. Infect. Dis. 2006; 54 (2): 149-153

Contemporary antimicrobial activity of triple antibiotic ointment: A multiphased study of recent clinical isolates in the United States and Australia.

Contemporary antimicrobial activity of triple antibiotic ointment: A multiphased study of recent clinical isolates in the United States and Australia. by Jones RN, Li Q., Kohut B, Biedenbach DJ, Bell J, Turnidge JD published in Diagn. Microbiol. Infect. Dis. 2006; 54 (1): 63-71

Oxazolidinone susceptibility patterns in 2004: Report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program assessing isolates from 16 nations.

Oxazolidinone susceptibility patterns in 2004: Report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program assessing isolates from 16 nations. by Jones, R.N., Ross, J.E., Fritsche, T.R., and Sader, H.S. published in J. Antimicrob. Chemother. 2006; 57 (2): 279-287

Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: A global surveillance report (2003-2004).

Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: A global surveillance report (2003-2004). by Watters AA, Jones RN, Leeds JA, Denys G, Sader HS and Fritsche TR published in J. Antimicrob. Chemother. 2006; 57 (5): 914-923

Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: Time for local guidelines?

Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: Time for local guidelines? by Andrade SS, Sader HS, Jones RN, Pereira AS, Pignatari ACC and Gales AC published in Mem. Inst. Oswaldo Cruz 2006; 101 (7): 741-748

Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: Report from the MYSTIC Program (1999-2005).

Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: Report from the MYSTIC Program (1999-2005). by Deshpande LM, Rhomberg PR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 56 (4): 367-372

Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: Results from an International Antimicrobial Surveillance Program.

Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: Results from an International Antimicrobial Surveillance Program. by Jones RN, Fritsche TR, Hogan PA and Sheehan DJ published in J. Clin. Microbiol. 2006; 44 (7): 2622-2625

Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: Report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America).

Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: Report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America). by Kirby JT, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 56 (1): 75-82

Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).

Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). by Rhomberg PR, Fritsche TR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2006; 56 (1): 57-62

Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): Initial results from an international surveillance protocol.

Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): Initial results from an international surveillance protocol. by Jones RN, Fritsche TR, Sader HS and Goldstein BP published in J. Chemother. 2005; 17 (6): 593-600

Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: Report from the Mystic Surveillance Program in the United States (2004).

Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: Report from the Mystic Surveillance Program in the United States (2004). by Rhomberg, PR, Fritsche, TR, Sader, HS, Jones, RN published in J. Chemother. 2005; 17 (5): 459-469